Viral complement regulatory proteins

Immunopharmacology

Volumn 42, Issue 1-3, 1999, Pages 99-106

  Rosengard, Ariella M ^a   M Ahearn, Joseph ^a  

^a NONE

Author keywords

Complement; Complement control proteins; Regulatory proteins

Indexed keywords

AUTACOID; COMPLEMENT; MEMBRANE PROTEIN; REGULATOR PROTEIN; VIRUS PROTEIN;

COMPLEMENT INHIBITION; CONFERENCE PAPER; HOST CELL; IMMUNE RESPONSE; INTERCELLULAR SPACE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; VIRUS ENVELOPE;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; HUMANS; VIRAL PROTEINS;

EID: 0033054391     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00012-0     Document Type: Conference Paper

References (61)

1. Ahearn J.M., Fischer M.B., Croix D.M., Goerg S., Ma. M., Xia J., Zhou X., Howard R.G., Rothstein T.L., Carroll M.C. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity. 4:1996;251-262.
2. Ahearn, J.M., Rosengard, A.M., 1998. Complement receptors. In: Volanakis, J.E., Frank, M.M. (Eds.), The Complement System in Health and Disease. Marcel Dekker, New York, pp. 167-202.
3. Albrecht J.C., Fleckenstein B. New member of the multigene family of complement control proteins in herpesvirus saimiri. J. Virology. 66:1992;3937-3940.
4. Albrecht, J.C., Fleckenstein, B., 1994. Complement regulatory proteins of herpesvirus saimiri. In: McFadden, G. (Eds.), Viroceptors, Virokines, and Related Immune Modulators Encoded by DNA Viruses. Landes, Austin, pp. 127-145.
5. Atkinson J.P., Farries T.C. Separation of self from non-self in the complement system. Immunol. Today. 8:1987;212-215.
6. Barquet N., Domingo P. Smallpox: The triumph over the most terrible of the ministers of death. Ann. Intern. Med. 127:1997;635-642.
7. Baxby, D., 1981. Jenner's Smallpox Vaccine. Heinemann Educational Books, London, UK.
8. Bergelson J.M., Chan M., Solomon K.R., St. John N.F., Lin H., Finberg R.W. Decay-accelerating factor (CD55), a glycosylphosphatidylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. Proc. Natl. Acad. Sci. U.S.A. 91:1994;6245-6248.
9. Boshoff C., Endo Y., Collins P.D., Takeuchi Y., Reeves J.D., Schweickart V.L., Siani M.A., Sasaki T., Williams T.J., Gray P.W., Moore P.S., Weiss R.A. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science (Washington DC). 278:1997;290-294.
10. Caras I.W., Davitz M.A., Rhee L., Weddell G., Martin D.W.J., Nussenzweig V. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature (London). 325:1987;545-549.
11. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., Moore P.S. Identification of new herpes virus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (Washington DC). 266:1994;1865-1869.
12. Cooper N.R., Moore M.D., Nemerow G.R. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Annu. Rev. Immunol. 6:1988;85-113.
13. Croix D.A., Ahearn J.M., Rosengard A.M., Han S., Kelsoe G., Ma M., Carroll M.C. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 183:1996;1745-1752.
14. Dorig R.E., Marcil A., Chopra A., Richardson C.D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell. 75:1993;295-305.
15. Englestad M., Howard S.T., Smith G.L. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology. 188:1992;801-810.
16. Fang Y., Xu C., Fu Y.-X., Holers V.M., Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 160:1998;5273-5279.
17. Fearon D.T. Regulation of the amplification of C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Natl. Acad. Sci. U.S.A. 76:1979;5867-5871.
18. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U.S.A. 81:1984;4510-4514.
19. Fischer M.B., Goerg S., Shen L., Prodeus A.P., Goodnow C.C., Kelsoe G., Carroll M.C. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science (Washington DC). 280:1998;582-585.
20. Fodor W.L., Rollins S.A., Bianco-Caron S., Rother R.P., Guilmette E.R., Burton W.V., Albrecht J.C., Fleckenstein B., Squinto S.P. The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J. Virol. 69:1995;3889-3892.
21. Frade R., Barel M., Ehlin-Henriksson B., Klein G. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. U.S.A. 82:1985;1490-1493.
22. Fujita R., Inoue T., Ogawa K., Iida K., Tamura N. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J. Exp. Med. 166:1987;1221-1228.
23. Hourcade D., Holers V.M., Atkinson J.P. The regulators of complement activation (RCA) gene cluster. Adv. Immunol. 45:1989;381-416.
24. Iida K., Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J. Exp. Med. 153:1981;1138-1150.
25. Isaacs S.N., Kotwal G.J., Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. U.S.A. 89:1992;628-632.
26. Isaacs S.N., Wolffe E.J., Payne L.G., Moss B. Characterization of a vaccinia virus-encoded 42-Kilodalton Class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66:1992;7217-7224.
27. Karnauchow T.M., Tolson D.L., Harrison B.A., Altman E., Lublin D.M., Dimock K. The HeLa cell receptor for enterovirus 70 is decay-accelerating factor (CD55). J. Virol. 70:1996;5143-5152.
28. Karp C.L., Wysocka M., Wahl L.M., Ahearn J.M., Cuomo P.J., Sherry B., Trinchieri G., Griffin D.E. Mechanism of suppression of cell-mediated immunity by measles virus. Science (Washington DC). 273:1996;228-231.
29. Kotwal G.J., Isaacs S.N., McKenzie R., Frank M.M., Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (Washington DC). 250:1990;827-830.
30. Kotwal G.J., Moss B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature (London). 335:1988;176-178.
31. Lachmann P.J. The control of homologous lysis. Immunol. Today. 12:1991;312-315.
32. Liszewski, M.K., Atkinson, J.P., 1998. Regulatory proteins of complement. In: Volanakis, J.E., Frank, M.M. (Eds.), The Complement System in Health and Disease. Marcel Dekker, New York, pp. 149-165.
33. Maisner A., Alvarez J., Liszewski M.K., Atkinson D.J., Atkinson J.P., Herrler G. The N-glycan of the SCR 2 region is essential for membrane cofactor protein (CD46) to function as a measles virus receptor. J. Virol. 70:1996;4973-4977.
34. Manchester M., Liszewski M.K., Atkinson J.P., Oldstone M.B. Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc. Natl. Acad. Sci. U.S.A. 91:1994;2161-2165.
35. Manchester M., Valsamakis A., Kaufman R., Liszewski M.K., Alvarez J., Atkinson J.P., Lublin D.M., Oldstone M.B. Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46). Proc. Natl. Acad. Sci. U.S.A. 92:1995;2303-2307.
36. McCrae M.A., Pennington T.H. Specific secretion of polypeptides from cells infected with vaccinia virus. J. Virol. 28:1978;828-834.
37. McKenzie R., Kotwal G.J., Moss B., Hammer C.H., Frank M.M. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166:1992;1245-1250.
38. Medof M.E., Iida K., Mold C., Nussenzweig V. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J. Exp. Med. 156:1982;1739-1754.
39. Miller C.G., Justus D.E., Jayaraman S., Kotwal G.J. Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: investigation of the role of host complement in poxvirus pathogenesis. Cell Immunol. 162:1995;326-332.
40. Miller C.G., Shchelkunov S.M., Kotwal G.J. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology. 229:1997;126-133.
41. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 93:1996;3357-3361.
42. Naniche D., Varior-Krishnan G., Cervoni F., Wild T.F., Rossi B., Rabourdin-Combe C., Gerlier D. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67:1993;6025-6032.
43. Nemerow G.R., Mold C., Schwend V.K., Tollefson B., Cooper N.R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of GP350 and C3 complement fragment C3d. J. Virol. 61:1987;1416-1420.
44. Nemerow G.R., Wolfert R., McNaughton M.E., Cooper N.R. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor. J. Virol. 55:1985;347-351.
45. Ogata R.T., Mathias P., Bradt B.M., Cooper N.R. Murine C4b-binding protein. Mapping of the ligand binding site and the N-terminus of the pre-protein. J. Immunol. 150:1993;2273-2280.
46. Rosengard A.M., Ahearn J.M. Creation and functional characterization of SPICE, the smallpox inhibitor of complement enzymes. Mol. Immunol. 35:1998;397. Abstr.
47. Rosengard A.M., Turka L.A., Korb L.C., Baldwin III W.M., Sanfilippo F., Ahearn J.M. Functional comparison of vaccinia virus complement-control protein and human CR1. Mol. Immunol. 33:1996;265. Abstr.
48. Rosse W.F. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine. 76:1997;63-93.
49. Russo J.J., Bohenzky R.A., Chien M.C., Chen J., Yan M., Maddalena D., Parry J.P., Peruzzi D., Edelman I.S., Chang Y., Moore P.S. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U.S.A. 93:1996;14862-14867.
50. 1 inactivates the alternative complement pathway. J. Immunol. 160:1998;5596-5604.
51. Saifuddin M., Parker C.J., Peeples M.E., Gorny M.K., Zolla-Pazner S., Ghassemi M., Rooney I.A., Atkinson J.P., Spear G.T. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182:1955;501-509.
52. Schmitz J., Zimmer J.P., Kluxen B., Aries S., Bogel M., Gigli I., Schmitz H. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J. Clin. Invest. 96:1995;1520-1526.
53. Seya T.J., Turner J.R., Atkinson J.P. Purification and characterization of a membrane protein (gp 45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163:1986;837-855.
54. Shafren D.R., Bates R.C., Agrez M.V., Herd R.L., Burns G.F., Barry R.D. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J. Virol. 69:1995;3873-3877.
55. Shchelkunov S.N. Functional organization of variola major and vaccinia virus genomes. Virus Genes. 10:1995;53-71.
56. Smith G.L., Symons J.A., Khanna A., Vanderplasschen A., Alcami A. Vaccinia virus immune evasion. Immunol. Rev. 159:1997;137-154.
57. Spear G.T., Lurain N.S., Parker C.J., Ghassemi M., Payne G.H., Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J. Immunol. 155:1995;4376-4381.
58. Vanderplasschen A., Mathew E., Hollinshead M., Sim R.B., Smith G.L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. U.S.A. 95:1998;7544-7549.
59. Virgin H.W., Latreille P., Wamsley P., Hallsworth K., Weck K.E., Dal Canto A.J., Speck S.H. Complete sequence and genomic analysis of murine gamma-herpesvirus 68. J. Virol. 71:1997;5894-5904.
60. Warmuth I., Moore P.S. Kaposi sarcoma, Kaposi sarcoma-associated herpesvirus, and human T-cell lymphotropic virus type 1: What is the current evidence for causality? Arch. Dermatology. 133:1997;83-85.
61. Wolffe E.J., Isaacs S.N., Moss B. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J. Virol. 67:1993;4732-4741.